News | August 13, 2025
Marksans Pharma reports Q1 FY26 gross profit 8.9% higher at Rs. 358.2 Cr
EBITDA stood at Rs. 100.1 crore with a margin of 16.1 per cent
EBITDA stood at Rs. 100.1 crore with a margin of 16.1 per cent
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
This strategic investment strengthens Cohance's integrated oligonucleotide platform
Minister releases five breakthrough veterinary technologies to strengthen diagnostics and combat antimicrobial resistance
Dr. Venkatraman brings over 25 years of experience in small molecule and Biologics drug development, manufacturing, and advancing strategic growth initiatives
Our specialty chemical businesses have continued to perform strongly, growing double digit YoY
The latest BioE3 policy builds the framework for high-performance biomanufacturing to propel the development and production
She was Group Chief Marketing Officer at CKA Birla Group in her last role
Upgrades 2025 full-year CDMO sales and margin outlook
Plant-based chemistries have an outsized role to play for the HPC sector by meeting demand for good, gentle, and green products
Subscribe To Our Newsletter & Stay Updated
